Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Completed 19Terminated 8Unknown 7Recruiting 6Withdrawn 3Not yet recruiting 3Active not recruiting 2

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 10Breast Neoplasms 10Ovarian Neoplasms 9Triple Negative Breast Neoplasms 8Endometrial Neoplasms 8Uterine Cervical Neoplasms 5Stomach Neoplasms 5Esophageal Neoplasms 5Squamous Cell Carcinoma of Head and Neck 4Fallopian Tube Neoplasms 4Recurrence 3Pancreatic Neoplasms 3Neoplasms 3Small Cell Lung Carcinoma 2NSCLC 2Mouth Neoplasms 2Laryngeal Neoplasms 2Carcinoma, Ovarian Epithelial 2Unresectable Locally Advanced or Metastatic Solid Tumors 1Thyroid Neoplasms 1Stage III and IV Ovarian Cancer 1Squamous Non-small Cell Lung Cancer 1Solid Tumor Cancer 1Sarcoma, Kaposi 1Respiratory Tract Neoplasms 1Platinum-sensitive Relapsed Ovarian Cancer 1Platinum-Resistant Primary Peritoneal Carcinoma 1Pancreatic Intraductal Neoplasms 1Pancreatic Cystic Neoplasm 1PDAC - Pancreatic Ductal Adenocarcinoma 1

Interventions

Cyclophosphamide 6fludarabine 5toripalimab 3Paclitaxel 3Etoposide 3Carboplatin 3Bevacizumab 3zimberelimab 2tislelizumab 2sintilimab 2glumetinib 2Vincristine 2Temozolomide 2Platinum 2Immune Checkpoint Inhibitors 2Hepatectomy 2Gemcitabine 2Drug Therapy 2Docetaxel 2Cisplatin 2Capecitabine 2venetoclax 1relmacabtagene autoleucel 1osimertinib 1lenvatinib 1irinotecan sucrosofate 1glofitamab 1gallium maltolate 1fludarabine phosphate 1eribulin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Not yet recruiting × Recurrence × Paclitaxel × Clear all
NCT06751277 2024-12-27

QL1706 Combined with Chemotherapy in the Treatment of Recurrent or Metastatic Endometrial Cancer

Peking Union Medical College Hospital

Phase 2 Not yet recruiting
26 enrolled
Gynecologic

Recurrence, Endometrial Neoplasms

NCT05798819 2023-04-05

A Study of GLS-010 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer

Guangzhou Gloria Biosciences Co., Ltd.

Phase 3 Not yet recruiting
424 enrolled

Recurrence

NCT05715840 2023-02-08

Efficacy and Safety Study of First-line Treatment With SG001 Plus Chemotherapy ± Bevacizumab Versus Placebo Plus Chemotherapy ±Bevacizumab for Recurrent, or Metastatic Cervical Cancer With PD-L1 Positive (CPS≥1)

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Phase 3 Not yet recruiting
368 enrolled

Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡